Pasar al contenido principal

UNA VISION GENOMICA Y EPIGENOMICA INTEGRADA DE LA HETEROGENEIDAD INTRATUMORAL DURANTE LA EVOLUCION DE LAS NEOPLASIAS LINFOBLASTICAS DE CELULAS T PRECURSORAS.

SAF2015-70561-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2015
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Dirección General de Investigación Científica y Técnica
Centro beneficiario UNIVERSIDAD AUTONOMA DE MADRID
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 13
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo científico (JournalArticle)

PIM1 is a potential therapeutic target for the leukemogenic effects mediated by JAK/STAT pathway mutations in T-ALL/LBL

  • Lahera, Antonio
  • Vela-Martín, Laura
  • Fernandez-Navarro, Pablo L
  • Llamas, Pilar
  • López-Lorenzo, José L
  • Cornago, Javier
  • Santos, Javier
  • Fernández-Piqueras, José
  • Villa-Morales, María
Precursor T-cell neoplasms (T-ALL/LBL) are aggressive hematological malignancies that arise from the malignant transformation of immature thymocytes. Despite the JAK/STAT pathway is recurrently altered in these neoplasms, there are not pharmacological inhibitors officially approved for the treatment of T-ALL/LBL patients that present oncogenic JAK/STAT pathway mutations. In the effort to identify potential therapeutic targets for those patients, we followed an alternative approach and focused on their transcriptional profile. We combined the analysis of molecular data from T-ALL/LBL patients with the generation of hematopoietic cellular models to reveal that JAK/STAT pathway mutations are associated with an aberrant transcriptional profile. Specifically, we demonstrate that JAK/STAT pathway mutations induce the overexpression of the PIM1 gene. Moreover, we show that the pan-PIM inhibitor, PIM447, significantly reduces the leukemogenesis, as well as the aberrant activation of c-MYC and mTOR pathways in cells expressing different JAK/STAT pathway mutations, becoming a potential therapeutic opportunity for a relevant subset of T-ALL/LBL patients.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

RNA-Seq reveals the existence of a CDKN1C-E2F1-TP53 axis that is altered in human T-cell lymphoblastic lymphomas

  • López-Nieva, Pilar
  • Fernández-Navarro, Pablo
  • Vaquero-Lorenzo, Concepción
  • Villa-Morales, María
  • Graña-Castro, Osvaldo
  • Cobos-Fernández, M. A.
  • López-Lorenzo, José L.
  • Llamas, Pilar
  • González-Sánchez, Laura
  • Sastre, Isabel
  • Pollán, Marina
  • Malumbres, Marcos
  • Santos, Javier
  • Fernández-Piqueras, José
Abstract Background Precursor T-cell lymphoblastic lymphomas (T-LBL) are rare aggressive hematological malignancies that mainly develop in children. As in other cancers, the loss of cell cycle control plays a prominent role in the pathogenesis in these malignancies that is primarily attributed to loss of CDKN2A (encoding protein p16INK4A). However, the impact of the deregulation of other genes such as CDKN1C, E2F1, and TP53 remains to be clarified. Interestingly, experiments in mouse models have proven that conditional T-cell specific deletion of Cdkn1c gene may induce a differentiation block at the DN3 to DN4 transition, and that the loss of this gene in the absence of Tp53 led to aggressive thymic lymphomas. Results In this manuscript, we demonstrated that the simultaneous deregulation of CDKN1C, E2F1, and TP53 genes by epigenetic mechanisms and/or the deregulation of specific microRNAs, together with additional impairing of TP53 function by the expression of dominant-negative isoforms are common features in primary human T-LBLs. Conclusions Previous experimental work in mice revealed that T-cell specific deletion of Cdkn1c accelerates lymphomagenesis in the absence of Tp53. If, as expected, the consequences of the deregulation of the CDKN1C-E2F1-TP53 axis were the same as those experimentally demonstrated in mouse models, the disruption of this axis might be useful to predict tumor aggressiveness, and to provide the basis towards the development of potential therapeutic strategiesin human T-LBL., The authors would like to thank Mario González-Sánchez and Javier González-Palacios ("Bioinformatics and Research Group in Genetic and Environmental Epidemiology", ISCIII) for their technical support. We thank all patients who were willing to donate their samples—without their support the research work would not be possible., The authors would like to thank the Spanish Ministry of Economy and Competitiveness (SAF2015–70561-R; MINECO/FEDER, EU) and the Autonomous Community of Madrid, Spain (B2017/BMD-3778; LINFOMAS-CM) for funding this work. Institutional grants from the Fundación Ramón Areces and Banco de Santander are also acknowledged. ORCID codes: 0000–0003– 4520-6785 to JFP and 0000–0002–4168-6251 to JS. The funding body did not play any role in the study design, collection, analysis, and interpretation of data and in writing the manuscript.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The use of PanDrugs to prioritize anticancer drug treatments in a case of T-ALL based on individual genomic data

  • Fernández-Navarro, Pablo
  • López-Nieva, Pilar
  • Piñeiro-Yañez, Elena
  • Carreño-Tarragona, Gonzalo
  • Martínez-López, Joaquín
  • Sánchez Pérez, Raúl
  • Aroca, Ángel
  • Al-Shahrour, Fátima
  • Cobos-Fernández, M. A.
  • Fernández-Piqueras, José
[Background] Acute T-cell lymphoblastic leukaemia (T-ALL) is an aggressive disorder derived from immature thymocytes. The variability observed in clinical responses on this type of tumours to treatments, the high toxicity of current protocols and the poor prognosis of patients with relapse or refractory make it urgent to find less toxic and more effective therapies in the context of a personalized medicine of precision., [Methods] Whole exome sequencing and RNAseq were performed on DNA and RNA respectively, extracted of a bone marrow sample from a patient diagnosed with tumour primary T-ALL and double negative thymocytes from thymus control samples. We used PanDrugs, a computational resource to propose pharmacological therapies based on our experimental results, including lists of variants and genes. We extend the possible therapeutic options for the patient by taking into account multiple genomic events potentially sensitive to a treatment, the context of the pathway and the pharmacological evidence already known by large-scale experiments., [Results] As a proof-of-principle we used next-generation-sequencing technologies (Whole Exome Sequencing and RNA-Sequencing) in a case of diagnosed Pro-T acute lymphoblastic leukaemia. We identified 689 disease-causing mutations involving 308 genes, as well as multiple fusion transcript variants, alternative splicing, and 6652 genes with at least one principal isoform significantly deregulated. Only 12 genes, with 27 pathogenic gene variants, were among the most frequently mutated ones in this type of lymphoproliferative disorder. Among them, 5 variants detected in CTCF, FBXW7, JAK1, NOTCH1 and WT1 genes have not yet been reported in T-ALL pathogenesis., [Conclusions] Personalized genomic medicine is a therapeutic approach involving the use of an individual’s information data to tailor drug therapy. Implementing bioinformatics platform PanDrugs enables us to propose a prioritized list of anticancer drugs as the best theoretical therapeutic candidates to treat this patient has been the goal of this article. Of note, most of the proposed drugs are not being yet considered in the clinical practice of this type of cancer opening up the approach of new treatment possibilities., This research was made possible through funding by the Spanish Ministry of Science, Innovation and Universities (RTI2018–093330-B_100); Spanish Ministry of Economy and Competitiveness (SAF2015–70561-R); MINECO/FEDER, EU; BES-2013-065740); Ramón Areces Foundation (CIVP19S7917); the Autonomous Community of Madrid, Spain (B2017/BMD-3778; LINFOMAS-CM); the Spanish Association Against Cancer (AECC, 2018; PROYE18054PIRI); and the Institute of Health Carlos III, ISCIII (ACCI-CIBERER-17). Institutional grants from the Ramón Areces Foundation and the Santander Bank to the Severo Ochoa Molecular Biology Center (CBMSO) are also acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Downregulation of specific FBXW7 isoforms with differential effects in T-cell lymphoblastic lymphoma

  • Vázquez-Domínguez, Irene
  • González-Sánchez, Laura
  • López-Nieva, Pilar
  • Fernández-Navarro, Pablo
  • Villa-Morales, María
  • Cobos-Fernández, M. A.
  • Sastre, Isabel
  • Fraga, Mario F.
  • Fernández, Agustín F.
  • Malumbres, Marcos
  • Salazar-Roa, María
  • Graña-Castro, Osvaldo
  • Santos, Javier
  • Llamas, Pilar
  • López-Lorenzo, José L.
  • Fernández-Piqueras, José
FBXW7 is a driver gene in T-cell lymphoblastic neoplasia acting through proteasome degradation of key proto-oncogenes. FBXW7 encodes three isoforms, α, β and γ, which differ only in the N-terminus. In this work, massive sequencing revealed significant downregulation of FBXW7 in a panel of primary T-cell lymphoblastic lymphomas characterised by the absence of mutations in its sequence. We observed that decreased expression mainly affected the FBXW7β isoform and to a lesser extent FBXW7α and may be attributed to the combined effect of epigenetic changes, alteration of upstream factors and upregulation of miRNAs. Transient transfections with miRNA mimics in selected cell lines resulted in a significant decrease of total FBXW7 expression and its different isoforms separately, with the consequent increment of critical substrates and the stimulation of cell proliferation. Transient inhibition of endogenous miRNAs in a T-cell lymphoblastic-derived cell line (SUP-T1) was capable of reversing these proliferative effects. Finally, we show how FBXW7 isoforms display different roles within the cell. Simultaneous downregulation of the α and γ isoforms modulates the amount of CCNE1, whilst the β-isoform alone was found to have a prominent role in modulating the amount of c-MYC. Our data also revealed that downregulation of all isoforms is a sine qua non condition to induce a proliferative pattern in our cell model system. Taking these data into account, potential new treatments to reverse downregulation of all or a specific FBXW7 isoform may be an effective strategy to counteract the proliferative capacity of these tumour cells., Spanish Ministry of Economy and Competitiveness (SAF2015-70561-R; MINECO/FEDER, EU; BES-2013-065740); the Autonomous Community of Madrid, Spain (B2017/BMD-3778; LINFOMAS-CM); the Spanish Association against Cancer (AECC, 2018; PROYE18054PIRI) and the Instituto de Salud Carlos III (ISCIII) (ACCI-CIBERER-17). Institutional grants from the Fundación Ramón Areces and Banco de Santander to the CBMSO are also acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

SOCS3 deregulation contributes to aberrant activation of the JAK/STAT pathway in precursor T-cell neoplasms

  • Lahera, Antonio
  • López-Nieva, Pilar
  • Alarcón, Hernán
  • Marín-Rubio, José L.
  • Cobos-Fernández, M. A.
  • Fernández-Navarro, Pablo
  • Fernández, Agustín F.
  • Vela-Martín, Laura
  • Sastre, Isabel
  • Ruiz-García, Sara
  • Llamas, Pilar
  • López-Lorenzo, José L.
  • Cornago, Javier
  • Santos, Javier
  • Fernández-Piqueras, José
  • Villa-Morales, María
Despite the Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway being frequently altered in T-ALL/LBL, no specific therapy has been approved for T-ALL/LBL patients with constitutive signalling by JAK/STAT, so there is an urgent need to identify pathway members that may be potential therapeutic targets. In the present study, we searched for JAK/STAT pathway members potentially modulated through aberrant methylation and identified SOCS3 hypermethylation as a recurrent event in T-ALL/LBL. Additionally, we explored the implications of SOCS3 deregulation in T-ALL/LBL and demonstrated that SOCS3 counteracts the constitutive activation of the JAK/STAT pathway through different molecular mechanisms. Therefore, SOCS3 emerges as a potential therapeutic target in T-ALL/LBL., This work was supported in part by funds from Ministerio de Economía y Competitividad (SAF2015-70561-R; MINECO/FEDER, EU to José Fernández-Piqueras and María Villa-Morales); Ministerio de Ciencia, Innovación y Universidades (RTI2018- 093330-B-I00; MCIU/FEDER, EU to José Fernández-Piqueras and Javier Santos); Fundación Ramón Areces (CIVP19S7917 to José Fernández-Piqueras); Comunidad de Madrid (B2017/BMD-3778; LINFOMAS-CM to José Fernández-Piqueras); Asociación Española Contra el Cáncer (AECC, 2018; PROYE18054PIRI to José Fernández-Piqueras); and Instituto de Investigación Sanitaria Fundación Jiménez Díaz to José Fernández-Piqueras; institutional grants from the Fundación Ramón Areces and Banco de Santander to the CBMSO are also acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Comprehensive characterization of a novel, oncogenic and targetable SEPTIN6::ABL2 fusion in T-ALL

  • Lahera, Antonio
  • Vela-Martín, Laura
  • López-Nieva, P.
  • Salgado, Rocío N.
  • Rodríguez-Perales, Sandra
  • Torres-Ruiz, Raúl
  • López-Lorenzo, Jose L
  • Cornago, Javier
  • Llamas, Pilar
  • Fernández-Navarro, Pablo
  • Sánchez-Domínguez, Rebeca
  • Segovia, Jose C.
  • Sastre, Isabel
  • Cobos-Fernández, María
  • Menéndez, Pablo
  • Santos, Javier
  • Fernández-Piqueras, José
  • Villa-Morales, María
descripción no proporcionada por scopus, This work was supported in part by funds from Ministerio de Economía y Competitividad (SAF2015-70561-R; MINECO/FEDER, EU to J.F.-P. and M.V.-M.); Ministerio de Ciencia, Innovación y Universidades (RTI2018-093330-B-I00; MCIU/FEDER, EU to J.F.-P. and J.S.); Fundación Ramón Areces (CIVP19S7917 to J.F.-P.); Comunidad de Madrid (B2017/BMD-3778; LINFOMAS-CM to J.F.-P.); Asociación Española Contra el Cáncer (AECC, 2018; PROYE18054PIRI to J.F.-P. and LABAE20049RODR to S.R-P.); Spanish National Research and Development Plan, Instituto de Salud Carlos III and FEDER (PI20/01837 to S.R.-P. and PI21/01641 to R.T.-R.); Proyecto Desarrollo Tecnológico (DTS19/00111 to S.R.-P.); Instituto de Investigación Sanitaria Fundación Jiménez Díaz to J.F.-P. Institutional grants from the Fundación Ramón Areces and Banco de Santander to the CBMSO; IAP-DRCLAS at Harvard and Fundación Asisa (086812) are also acknowledged.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The JAK3Q988P mutation reveals oncogenic potential and resistance to ruxolitinib

  • Lahera, Antonio
  • Vela-Martín, Laura
  • Fernández-Navarro, Pablo
  • Llamas, Pilar
  • López-Lorenzo, José L.
  • Cornago, Javier
  • Santos, Javier
  • Fernández-Piqueras, José
  • Villa-Morales, María
T-cell acute lymphoblastic leukemia (T-ALL) arises from the malignant transformation of T-cell progenitors at various differentiation stages. Given that patients who relapse have a dismal prognosis, there is an urgent need to identify the molecular alterations that are present in such patients and promote leukemogenesis to implement personalized therapies with higher efficacy and fewer adverse effects. In the present manuscript, we identified the JAK3 mutation in a T-ALL patient who did not achieve a durable response after the conventional treatment and whose tumor cells at relapse presented constitutive activation of the JAK/STAT pathway. Although JAK3 has been previously identified in T-ALL patients from different studies, the functional consequences exerted by this mutation remain unexplored. Through the combination of different hematopoietic cellular models, we functionally characterize JAK3 as an oncogenic mutation that contributes to leukemogenesis. Notably, JAK3 not only promotes constitutive activation of the JAK/STAT pathway in the absence of cytokines and growth factors, as is the case for other JAK3 mutations that have been functionally characterized as oncogenic, but also functions independently of JAK1 and IL2RG, resulting in high oncogenic potential as well as resistance to ruxolitinib. Our results indicate that ruxolitinib may not be efficient for future patients bearing the JAK3 mutation who instead may obtain greater benefits from treatments involving other pharmacological inhibitors such as tofacitinib., This work was supported in part by funds from Ministerio de Economía y Competitividad (SAF2015‐70561‐R; MINECO/ FEDER, EU to J.F.‐P. and M.V.‐M.); Ministerio de Ciencia, Innovación y Universidades (RTI2018‐093330‐B‐I00; MCIU/FEDER, EU to J.F.‐P. and J.S.); Fundación Ramón Areces (CIVP19S7917 to J.F.‐P.); Comunidad de Madrid (B2017/BMD‐3778; LINFOMAS‐CM to J.F.‐P.); Asociación Española Contra el Cáncer (AECC, 2018; PROYE18054PIRI to J.F.‐P.); and Instituto de Investigación Sanitaria Fundación Jiménez Díaz to J.F.‐P.; institutional grants from the Fundación Ramón Areces and Banco de Santander to the CBMSO are also acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A Dual Role for FADD in Human Precursor T-Cell Neoplasms

  • Marín-Rubio, José Luis
  • Vela-Martín, Laura
  • Gudgeon, Jack
  • Pérez-Gómez, Eduardo
  • Sidgwick, Frances R
  • Trost, Matthias
  • Cunningham, Debbie L
  • Santos, Javier
  • Fernández-Piqueras, José
  • Villa-Morales, María
A reduction in FADD levels has been reported in precursor T-cell neoplasms and other tumor types. Such reduction would impact on the ability of tumor cells to undergo apoptosis and has been associated with poor clinical outcomes. However, FADD is also known to participate in non-apoptotic functions, but these mechanisms are not well-understood. Linking FADD expression to the severity of precursor T-cell neoplasms could indicate its use as a prognostic marker and may open new avenues for targeted therapeutic strategies. Using transcriptomic and clinical data from patients with precursor T-cell neoplasms, complemented by in vitro analysis of cellular functions and by high-throughput interactomics, our results allow us to propose a dual role for FADD in precursor T-cell neoplasms, whereby resisting cell death and chemotherapy would be a canonical consequence of FADD deficiency in these tumors, whereas deregulation of the cellular metabolism would be a relevant non-canonical function in patients expressing FADD. These results reveal that evaluation of FADD expression in precursor T-cell neoplasms may aid in the understanding of the biological processes that are affected in the tumor cells. The altered biological processes can be of different natures depending on the availability of FADD influencing its ability to exert its canonical or non-canonical functions. Accordingly, specific therapeutic interventions would be needed in each case., SAF2015-70561/Ministry of Economy, Industry and Competitiveness B2017/BMD-3778; LINFOMAS-CM/Comunidad de Madrid ACCI-CIBERER-17 ISCIII/Instituto de Salud Carlos III FPU13/00338/Ministerio de Educación Cultura y Deporte JLMR/Federation of European Biochemical Societies
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Differential molecular response in mice and human thymocytes exposed to a combined-dose radiation regime

  • López-Nieva, Pilar
  • González-Vasconcellos, Iria
  • González-Sánchez, Laura
  • Cobos-Fernández, María A.
  • Ruiz-García, Sara
  • Sánchez Pérez, Raúl
  • Aroca, Ángel
  • Fernández-Piqueras, José
  • Santos, Javier
In the quest for more effective radiation treatment options that can improve both cell killing and healthy tissue recovery, combined radiation therapies are lately in the spotlight. The molecular response to a combined radiation regime where exposure to an initial low dose (priming dose) of ionizing radiation is administered prior to a subsequent higher radiation dose (challenging dose) after a given latency period have not been thoroughly explored. In this study we report on the differential response to either a combined radiation regime or a single challenging dose both in mouse in vivo and in human ex vivo thymocytes. A differential cell cycle response including an increase in the subG1 fraction on cells exposed to the combined regime was found. Together with this, a differential protein expression profiling in several pathways including cell cycle control (ATM, TP53, p21), damage response (γH2AX) and cell death pathways such as apoptosis (Cleaved Caspase-3, PARP1, PKCδ and H3T45ph) and ferroptosis (xCT/GPX4) was demonstrated. This study also shows the epigenetic regulation following a combined regime that alters the expression of chromatin modifiers such as DNMTs (DNMT1, DNMT2, DNMT3A, DNMT3B, DNMT3L) and glycosylases (MBD4 and TDG). Furthermore, a study of the underlying cellular status six hours after the priming dose alone showed evidence of retained modifications on the molecular and epigenetic pathways suggesting that the priming dose infers a “radiation awareness phenotype” to the thymocytes, a sensitization key to the differential response seen after the second hit with the challenging dose. These data suggest that combined-dose radiation regimes could be more efficient at making cells respond to radiation and it would be interesting to further investigate how can these schemes be of use to potential new radiation therapies., This work was supported by the Spanish Ministry of Economy and Competitiveness (SAF2015-70561-R; MINECO/FEDER, EU); the Autonomous Community of Madrid, Spain (B2017/BMD-3778; LINFOMAS-CM) and the Spanish Association Against Cancer (AECC, 2018; PROYE18054PIRI). Institutional grants from the Fundación Ramón Areces and Banco de Santander are also acknowledged. The Spanish Ministry and the Juan de la Cierva fellowship program must be acknowledged for I.G.V. contract (IJCI-2016-29155).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

PIM1 is a potential therapeutic target for the leukemogenic effects mediated by JAK/STAT pathway mutations in T-ALL/LBL

  • Lahera, Antonio
  • Vela-Martín, Laura
  • Fernández-Navarro, Pablo
  • Llamas, Pilar
  • López-Lorenzo, José L
  • Cornago, Javier
  • Santos, Javier
  • Fernández-Piqueras, José
  • Villa-Morales, María
Precursor T-cell neoplasms (T-ALL/LBL) are aggressive hematological malignancies that arise from the malignant transformation of immature thymocytes. Despite the JAK/STAT pathway is recurrently altered in these neoplasms, there are not pharmacological inhibitors officially approved for the treatment of T-ALL/LBL patients that present oncogenic JAK/STAT pathway mutations. In the effort to identify potential therapeutic targets for those patients, we followed an alternative approach and focused on their transcriptional profile. We combined the analysis of molecular data from T-ALL/LBL patients with the generation of hematopoietic cellular models to reveal that JAK/STAT pathway mutations are associated with an aberrant transcriptional profile. Specifically, we demonstrate that JAK/STAT pathway mutations induce the overexpression of the PIM1 gene. Moreover, we show that the pan-PIM inhibitor, PIM447, significantly reduces the leukemogenesis, as well as the aberrant activation of c-MYC and mTOR pathways in cells expressing different JAK/STAT pathway mutations, becoming a potential therapeutic opportunity for a relevant subset of T-ALL/LBL patients., This work was supported in part by funds from Ministerio de Economía y Competitividad (SAF2015-70561-R; MINECO/FEDER, EU to J.F.-P. and M.V.-M.); Ministerio de Ciencia, Innovación y Universidades (RTI2018- 093330-B-I00; MCIU/FEDER, EU to J.F.-P. and J.S.); Fundación Ramón Areces (CIVP19S7917 to J.F.-P.); Comunidad de Madrid (B2017/BMD-3778; LINFOMAS-CM to J.F.-P.); Asociación Española Contra el Cáncer (AECC, 2018; PROYE18054PIRI to J.F.-P.); and Instituto de Investigación Sanitaria Fundación Jiménez Díaz to J.F.-P.; institutional grants from the Fundación Ramón Areces and Banco de Santander to the CBM are also acknowledged.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Improved identification of T-ALL paediatric patients with low MRD but poor prognosis using a transcriptional signature

  • Lahera, Antonio
  • Vela-Martín, Laura
  • Fernández-Navarro, Pablo
  • López-Lorenzo, José Luis
  • Cornago, Javier
  • Llamas, Pilar
  • Fresno, Manuel
  • Santos, Javier
  • Villa-Morales, María
T-cell acute lymphoblastic leukaemia (T-ALL) is an aggres-sive haematological malignancy that results from the malig-nant transformation of immature thymocytes and exhibitsa heterogeneous molecular landscape.1 Current standard-of-care treatments for T-ALL mainly consist of high-dosemulti-agent chemotherapy and achieve reasonable rates ofinitial complete responses that can reach up to 90% in chil-dren. However, refractory or relapsed patients have a dismalprognosis with survival rates below 10%; hence, most effortsare focused on optimizing first-line treatments and furtherimproving their efficacy. In this context, prognostic mark-ers capable of stratifying patients according to their poten-tial risk are essential, so high-risk patients may benefit frommore intensive chemotherapy regimens or haematopoieticstem cell transplantation, while low-risk patients may bene-fit from less intensive treatment approaches, which are char-acterized by reduced toxicity levels and fewer side effects, Ministerio de Ciencia, Innovación y Universidades, Grant/Award Number: RTI2018-093330-B-I00; Ministerio deEconomía y Competitividad, Grant/Award Number:SAF2015-70561-R; Instituto de Investigación Sanitaria Fundación Jiménez Díaz; Ministerio de Ciencia e Innovación,Grant/Award Number: PID2022-137487OB-I00.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Detection of novel fusion-transcripts by RNA-Seq in T-cell lymphoblastic lymphoma

  • López Nieva, Pilar
  • Fernández Navarro, Pablo
  • Graña-Castro, Osvaldo
  • Andrés-León, Eduardo
  • Santos, Javier
  • Villa-Morales, María
  • Cobos- Fernández, María Ángeles
  • González-Sánchez, Laura
  • Malumbres, Marcos
  • Salazar Roa, María
  • Fernández-Piqueras, José
Fusions transcripts have been proven to be strong drivers for neoplasia-associated mutations, although their incidence in T-cell lymphoblastic lymphoma needs to be determined yet. Using RNA-Seq we have selected 55 fusion transcripts identified by at least two of three detection methods in the same tumour. We confirmed the existence of 24 predicted novel fusions that had not been described in cancer or normal tissues yet, indicating the accuracy of the prediction. Of note, one of them involves the proto oncogene TAL1. Other confirmed fusions could explain the overexpression of driver genes such as COMMD3-BMI1, LMO1 or JAK3. Five fusions found exclusively in tumour samples could be considered pathogenic (NFYG-TAL1, RIC3-TCRBC2, SLC35A3-HIAT1, PICALM MLLT10 and MLLT10-PICALM). However, other fusions detected simultaneously in normal and tumour samples (JAK3-INSL3, KANSL1-ARL17A/B and TFG-ADGRG7) could be germ-line fusions genes involved in tumour-maintaining tasks. Notably, some fusions were confirmed in more tumour samples than predicted, indicating that the detection methods underestimated the real number of existing fusions. Our results highlight the potential of RNA-Seq to identify new cryptic fusions, which could be drivers or tumour-maintaining passenger genes. Such novel findings shed light on the searching for new T-LBL biomarkers in these haematological disorders.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Comprehensive characterization of a novel, oncogenic and targetable SEPTIN6::ABL2 fusion in T-ALL

  • Lahera, Antonio|||0000-0002-8899-1376
  • Vela Martín, Laura|||0000-0001-9435-8668
  • López Nieva, Pilar|||0000-0001-6369-2444
  • Salgado Sánchez, Rocío Nieves|||0000-0003-1678-8982
  • Rodriguez-Perales, Sandra|||0000-0001-7221-3636
  • Torres-Ruiz, Rocío
  • López Lorenzo, José L.|||0000-0003-1502-3902
  • Cornago, Javier|||0000-0002-0737-4211
  • Llamas, Pilar
  • Fernández-Navarro, Pablo|||0000-0001-9427-2581
  • Sánchez Domínguez, Rebeca
  • Segovia, Jose C.|||0000-0003-4101-6124
  • Sastre, Isabel
  • Cobos Fernández, María Á.
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
  • Santos Hernández, Javier|||0000-0002-4168-6251
  • Fernández Piqueras, José
  • Villa Morales, María